Monday - May 19, 2025

LOGIN  |  REGISTER
Amneal Pharmaceuticals
Cue Biopharma

Baxter to Present at Citi - 2025 Medtech & Life Sciences Access Day

February 13, 2025 | Last Trade: US$31.66 0.62 2.00

DEERFIELD, Ill. / Feb 13, 2025 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Citi - 2025 Medtech & Life Sciences Access Day on Thursday, February 27, 2025. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.

The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, August 26, 2025.

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page